Harrow Health, Inc. 8.625% Senior Notes due 2026
HROWL
Updated: 22/09/2026, 18:11:19
Harrow, Inc. is a pharmaceutical company that specializes in the development, production, and distribution of innovative medications. Its business activities are primarily divided into two segments: Pharmaceutical Compounding and Pharmaceutical Drug Development. The Pharmaceutical Compounding division notably encompasses the operations of the ImprimisRx business. Co-founded by Mark L. Baum and Robert J. Kammer in January 2006, the firm maintains its corporate headquarters in Nashville, Tennessee.
No summaries found.
- Share price
- $25.61
- Market cap
- $1.37B
- Exchange
- NASDAQ
- Currency
- USD
- CEO
- Mark L. Baum
- Employees
- 217
- IPO date
- 07/05/2021
- Beta
- 0.13720348
- Last dividend
- $0.00
- Day range
- $25.53 – $25.63
- 52-week range
- $25.00 – $25.72
- 1-day performance
- 0.19%
- 1-year performance
- 2.44%
- Current drawdown (1Y)
- -0.43%
- CIK
- 0001360214
- CUSIP
- N/A
- ISIN
- US4158582084
- Created
- 07/12/2025, 04:35:27
- Last update
- 22/09/2026, 18:11:19
Track Harrow Health, Inc. 8.625% Senior Notes due 2026 with an AI analyst
See which prediction-market events move HROWL, how its filings map to real-world exposure, and what 12 AI strategies are doing with positions like it.
Free forever to follow AlphaBrain’s AI strategies. No card required.
No news found for this symbol.